- Home
- CASI vs OXBR Comparison
CASI vs OXBR Comparison
Compare CASI & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- OXBR
- Stock Information
- Founded
- CASI 1991
- OXBR 2013
- Country
- CASI China
- OXBR Cayman Islands
- Employees
- CASI N/A
- OXBR N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- OXBR Property-Casualty Insurers
- Sector
- CASI Health Care
- OXBR Finance
- Exchange
- CASI Nasdaq
- OXBR Nasdaq
- Market Cap
- CASI 20.5M
- OXBR 16.9M
- IPO Year
- CASI 1996
- OXBR 2014
- Fundamental
- Price
- CASI $1.40
- OXBR $2.21
- Analyst Decision
- CASI Strong Buy
- OXBR Strong Buy
- Analyst Count
- CASI 1
- OXBR 1
- Target Price
- CASI $4.00
- OXBR $5.00
- AVG Volume (30 Days)
- CASI 313.5K
- OXBR 191.0K
- Earning Date
- CASI 08-15-2025
- OXBR 08-07-2025
- Dividend Yield
- CASI N/A
- OXBR N/A
- EPS Growth
- CASI N/A
- OXBR N/A
- EPS
- CASI N/A
- OXBR N/A
- Revenue
- CASI $31,368,000.00
- OXBR $1,363,000.00
- Revenue This Year
- CASI N/A
- OXBR $497.99
- Revenue Next Year
- CASI N/A
- OXBR $42.14
- P/E Ratio
- CASI N/A
- OXBR N/A
- Revenue Growth
- CASI 8.39
- OXBR N/A
- 52 Week Low
- CASI $1.09
- OXBR $1.27
- 52 Week High
- CASI $7.67
- OXBR $5.81
- Technical
- Relative Strength Index (RSI)
- CASI 44.81
- OXBR 61.45
- Support Level
- CASI $1.23
- OXBR $1.85
- Resistance Level
- CASI $1.50
- OXBR $2.26
- Average True Range (ATR)
- CASI 0.12
- OXBR 0.26
- MACD
- CASI 0.03
- OXBR 0.05
- Stochastic Oscillator
- CASI 78.05
- OXBR 83.33
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.